Deena Graham

Clinical trials

• Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers

  Principal investigator · Terminated

  Cota Inc.

  2017–2018
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

  Site PI · Recruiting · Phase 3

  Alliance for Clinical Trials in Oncology

  2025–2037
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  Site PI · Recruiting · Phase 3

  Stemline Therapeutics, Inc.

  2024–2032
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  Site PI · Recruiting · Phase 3

  NRG Oncology

  2023–2034